Cited by 269Antiplatelet Therapy and Cardiovascular DiseasesAtrial Fibrillation Management and OutcomesCoronary Interventions and Diagnostics

Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation

Open access
Ruiz-Nodar, Juan M., Marín, Francisco, Hurtado, José Antonio, Valencia, José, Pinar, Eduardo, Pineda, Javier, Gimeno, Juan Ramón, Sogorb, Francisco +2 more·2008·Journal of the American College of Cardiology

Abstract

Objectives This study was designed to review outcomes in relation to antithrombotic therapy management strategies for patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) with stenting.Background There is limited evidence on the optimal antithrombotic therapy management strategies for patients with AF who undergo PCI with stenting.Methods We reviewed 426 patients (70.9% men, mean age 71.5 +/- 8.5 years) with AF undergoing PCI with stenting between 2001 and 2006. We recorded clinical and demographic characteristics of the patients, stroke risk factors, and antithrombotic therapy use before PCI and at discharge. Clinical follow-up was performed, and all bleeding episodes, thromboembolism, and major adverse cardiac events (MACE) (i.e., death, acute myocardial infarction, or target lesion revascularization) were recorded.Results The most commonly associated comorbidities were hypertension (74.5%), diabetes mellitus (40.2%), chronic renal failure (14.9%), and congestive heart failure (26.7%); 80% of patients had >or=2 stroke risk factors. Of the drugs prescribed at discharge, aspirin plus clopidogrel were used in 174 patients (40.8%), whereas 213 patients (50%) were discharged with triple therapy (coumarins, aspirin, and clopidogrel). Complete follow-up was achieved in 87.5% (median 594 days; range 0 to 2,190). The incidence of adverse events was high (36.6%), with major bleeding in 12.3%, thromboembolic events in 4.2%, and MACE in 32.3%. All-cause mortality was high (22.6%). In a multivariate analysis, non-anticoagulation with coumarins increased mortality (17.8% vs. 27.8%; hazard ratio [HR] = 3.43; 95% confidence interval [CI] 1.61 to 7.54; p = 0.002) and MACE (26.5% vs. 38.7%; HR = 4.9; 95% CI 2.17 to 11.1; p < 0.01) In a Cox-regression analysis, non-anticoagulation (p < 0.01) and age (p = 0.02) were independent predictors of MACE.Conclusions Patients with AF undergoing PCI with stenting represent a high-risk population because of age, comorbidities, and presence of stroke risk factors. These patients have a high mortality and MACE rate, which is reduced by anticoagulation therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2007.11.035

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ruiz-Nodar, J. M., Marín, F., Hurtado, J. A., Valencia, J., Pinar, E., Pineda, J., Gimeno, J. R., Sogorb, F., Valdés, M., & Lip, G. Y. H.
Affiliations
  • Hospital General Universitario de Alicante Doctor Balmis (ES)
  • Instituto de Salud Carlos III (ES)
  • Hospital Universitario Virgen de la Arrixaca (ES)
  • Birmingham City Hospital (GB)
Corresponding author
Lip, Gregory Y.H.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2008-02
Volume
51
Issue
8
Pages
818-825
ISSN
0735-1097 (ISSN-L)
OpenAlex
W1475865131
Cited by
269
References
25
Citations by year
2026: 3 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 10 · 2020: 3 · 2019: 10 · 2018: 11 · 2017: 7 · 2016: 16 · 2015: 33 · 2014: 24 · 2013: 27 · 2012: 15
FWCI
24.00
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Surgery › Coronary Interventions and Diagnostics
Keywords
atrial fibrillation, percutaneous coronary intervention, coronary stenting, antithrombotic therapy, anticoagulation, antiplatelet therapy, clopidogrel, aspirin, coumarins, triple therapy, major adverse cardiac events, major bleeding, thromboembolism, all-cause mortality, stroke risk factors, dual antiplatelet therapy
MeSH terms
Aged, Anticoagulants, Atrial Fibrillation, Female, Heart Diseases, Humans, Male, Platelet Aggregation Inhibitors, Prognosis, Retrospective Studies, Risk Factors, Thromboembolism, Stents, Angioplasty, Balloon, Coronary, Postoperative Hemorrhage

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review